Clinical Trials on Hormone Sensitive Metastatic Prostate Cancer in United States

Total 9017 results

Imperial College London
Wellcome Trust

Recruiting

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (IP2-ATLANTA)

Prostate Cancer | Metastatic Prostate Cancer

United Kingdom
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
AstraZeneca
Parexel

Completed

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC)

Progressive Metastatic Castrate-Resistant Prostate Cancer

United States, Spain, Belgium, France, Korea, Republic of
M.D. Anderson Cancer Center

Recruiting

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Fatigue | Metastatic Cancers

United States
Ryan Kohlbrenner, MD
Radiological Society of North America

Completed

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...

United States
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Stanford University
National Cancer Institute (NCI)

Active, not recruiting

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Prostate Cancer | Neoplasms of Prostate | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Suspended

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic

Completed

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United Kingdom, Netherlands, Finland
Duke University
United States Department of Defense; Prostate Cancer Foundation; Janssen Diagnostics...

Completed

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method (CTC-EMT)

Metastatic Progressive Castration-resistant Prostate Cancer | Metastatic Progressive Breast Cancer

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Northwestern University
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Active, not recruiting

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Progressive Disease | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Arvinas Androgen Receptor, Inc.

Active, not recruiting

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

United States
University of California, San Francisco
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Not yet recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Zenith Epigenetics
Astellas Pharma Inc; Newsoara Biopharma Co., Ltd.

Recruiting

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States, China
AstraZeneca
Merck Sharp & Dohme LLC

Completed

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer

Belgium, France, Italy, Netherlands, Poland, United States, Canada, Czechia, Russian Federation, United Kingdom, Spain
Institute of Cancer Research, United Kingdom
Sun Pharmaceutical Industries Limited

Terminated

Abiraterone Acetate in Combination With Tildrakizumab (ACTIon)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
University of Southern California
National Cancer Institute (NCI); Mayo Clinic

Active, not recruiting

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

Breast Cancer | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
Roswell Park Cancer Institute

Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center

Completed

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
POINT Biopharma, a wholly owned subsidiary of Eli...

Active, not recruiting

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, Sweden, France, United Kingdom
National Cancer Institute (NCI)

Completed

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery

Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
OncoC4, Inc.
Prostate Cancer Clinical Trials Consortium

Recruiting

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (PRESERVE-006)

Metastatic Castration-resistant Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Austria, Singapore, Australia, Netherlands, France, Japan, Taiwan, Canada
Rahul Aggarwal
Merck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
University of Washington
National Cancer Institute (NCI)

Withdrawn

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Microsatellite Instability | Hormone-Resistant Prostate Cancer | Castration Levels of Testosterone

United States
Jonsson Comprehensive Cancer Center
Progenics Pharmaceuticals, Inc.

Terminated

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)

Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...

United States
Arvinas Androgen Receptor, Inc.

Recruiting

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Prostate Cancer Metastatic

United States
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Amgen

Active, not recruiting

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States

Clinical Trials on Hormone Sensitive Metastatic Prostate Cancer in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations